Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

20/20 To Air 'Justice For Faith' Friday, Oct. 30
On Sept. 7, 2012, University of North Carolina sophomore Faith Hedgepeth was found murdered in her off-campus apartment, leaving her family and friends devastated and...
Fri Oct 30, 2026

UNC graduate student took data science to the hardwood
As an undergraduate student at North Carolina, Boris Crnjak homed in on statistics and data science as his fields of study. “I’ll figure out the...
Thu Oct 29, 2026

Video: Carolina Calling - Eric Church Interview
Tommy Ashley and Joey Powell of inside Carolina speak with Tar Heel super-fan and 11-time Grammy nominee Eric Church about the Bill Belichick experiment in...
Tue Oct 27, 2026

Former UNC student Faith Hedgepeth's killer sentenced to life in prison without parole
A jury found Miguel Salguero-Olivares guilty of first-degree murder, first-degree rape, first-degree sexual offense, and first-degree burglary in the killing of UNC student Faith Hedgepeth...
Sat Oct 24, 2026